Table 3. SUV _max change overall and two subgroups.

Location	Overall (n = 60)			nLM (n = 44)			pLM (n = 16)			p for B nLM vs pLM
	B	F	p	B	F	p	B	F	p
RE	0.77	0.98	0.07	0.75	0.98	0.77	0.92	0.99	0.64	0.18
RLH	0.71	0.92	0.07	0.66	0.82	0.06	0.96	0.99	0.75	0.05
RRL	0.86	1.02	0.10	0.82	0.91	0.09	1.29	1.35	0.72	0.03
RU	0.80	0.96	0.07	0.74	0.87	0.08	1.00	1.01	0.49	0.04
RLL	0.87	1.01	0.08	0.86	0.98	0.12	0.95	1.13	0.42	0.47
RRI	0.74	0.77	0.32	0.73	0.75	0.39	0.90	0.95	0.66	0.16
RP	0.89	1.02	0.16	0.89	0.98	0.44	0.89	1.19	0.10	0.83
RLI	0.68	0.82	0.07	0.66	0.78	0.18	0.72	0.86	0.28	0.71
P	0.88	0.97	0.08	0.75	0.95	0.13	0.9	1.04	0.45	0.12
p-value	0.02	0.01		0.04	0.03		0.43	0.15

Note: SUV _max - Maximum standardized uptake value; B – Baseline; F – Follow-up; pLM – positive Lymphatic Metastasis; nLM – negative Lymphatic Metastasis; RE – Epigastric Region; RLH – Left Hypochondriac Region; RRL – Right Lumbar Region; RU – Umbilical Region; RLL – Left Lumbar Region; RRI – Right Inguinal Region; RP – Hypogastric (Pubic) Region; RLI – Left Inguinal Region; P – Pelvic Cavity.